in

Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases – Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases - Jasper Therapeutics (NASDAQ:JSPR)

  • Jasper Therapeutics Inc JSPR will focus on developing its lead product candidate, briquilimab (formerly JSP191), in chronic diseases and stem cell transplants for rare diseases.
  • This portfolio includes a new program on chronic urticaria, along with the company’s existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia, and severe combined immunodeficiency (SCID).
  • Based on preclinical and clinical studies showing inhibition of c-Kit signaling and depletion of mast cells, Jasper has prioritized starting a clinical study in severe chronic urticaria. 
  • While the company has no near-term plans to initiate a Phase 3 study in AML/MDS, it will continue to work with the FDA to explore development pathways and ensure briquilimab remains ready for a pivotal Phase 3 study in AML/MDS stem cell transplant.
  • Last week, Jasper Therapeutics announced data from the first three participants in a Phase 1/2 trial of adding briquilimab to an existing bone marrow transplantation regimen in individuals with sickle cell disease and beta-thalassemia.
  • Price Action: JSPR shares are up 13.20% at $1.80 on the last check Tuesday.

Written by biedex markets